SMPDB 2.0: big improvements to the Small Molecule Pathway Database.

Jewison T, Su Y, Disfany FM, Liang Y, Knox C, Maciejewski A, Poelzer J, Huynh J, Zhou Y, Arndt D, Djoumbou Y, Liu Y, Deng L, Guo AC, Han B, Pon A, Wilson M, Rafatnia S, Liu P, Wishart DS. · 2014

Read SMPDB 2.0: big improvements to the Small Molecule Pathway Database. by Jewison T, Su Y, Disfany FM, Liang Y, Knox C, Maciejewski A, Poelzer J, Huynh J, Zhou Y, Arndt D, Djoumbou Y, Liu Y, Deng L, Guo AC, Han B, Pon A, Wilson M, Rafatnia S, Liu P, Wishart DS. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3965088.txt.

Introduction

Timothy Jewison and colleagues release version 2.0 of the Small Molecule Pathway Database in Nucleic Acids Research in 2014. SMPDB draws human pathways for metabolism, drug action, drug breakdown, body processes, and metabolic disease as detailed, colorful, fully linked diagrams. It holds over 600 pathways, and nearly three quarters of them appear in no other database. Each diagram ties to information on tissues, organs, cell compartments, cofactors, and chemical structures.

Since the 2010 release, the pathway count grew by more than 70 percent, and every older diagram was redrawn, standardized, corrected, and enriched. Many pathways now include the transporter proteins that move molecules across membranes, plus richer detail on where each reaction happens in the body.

Catalog record

CREATORJewison T, Su Y, Disfany FM, Liang Y, Knox C, Maciejewski A, Poelzer J, Huynh J, Zhou Y, Arndt D, Djoumbou Y, Liu Y, Deng L, Guo AC, Han B, Pon A, Wilson M, Rafatnia S, Liu P, Wishart DS.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3965088

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

SMPDB 2.0: Big Improvements to the Small Molecule Pathway Database By Timothy Jewison, Yilu Su, Fatemeh Miri Disfany, Yongjie Liang, Craig Knox, Adam Maciejewski, Jenna Poelzer, Jessica Huynh, You Zhou, David Arndt, Yannick Djoumbou, Yifeng Liu Published in: Nucleic Acids Research DOI: 10.1093/nar/gkt1067 ABSTRACT Abstract The Small Molecule Pathway Database (SMPDB, http://www.smpdb.ca) is a comprehensive, colorful, fully searchable and highly interactive database for visualizing human metabolic, drug action, drug metabolism, physiological activity and metabolic disease pathways. SMPDB contains >600 pathways with nearly 75% of its pathways not found in any other database. All SMPDB pathway diagrams are extensively hyperlinked and include detailed information on the relevant tissues, organs, organelles, subcellular compartments, protein cofactors, protein locations, metabolite locations, chemical structures and protein quaternary structures. Since its last release in 2010, SMPDB has undergone substantial upgrades and significant expansion. In particular, the total number of pathways in SMPDB has grown by >70%. Additionally, every previously entered pathway has been completely redrawn, standardized, corrected, updated and enhanced with additional molecular or cellular information. Many SMPDB pathways now include transporter proteins as well as much more physiological, tissue, target organ and reaction compartment data. Thanks to the development of a standardized pathway drawing tool (called PathWhiz) all SMPDB pathways are now much more easily drawn and far more rapidly updated. PathWhiz has also allowed all SMPDB pathways to be saved in a BioPAX format. Significant improvements to SMPDB’s visualization interface now make the browsing, selection, recoloring and zooming of pathways far easier and far more intuitive. Because of its utility and breadth of coverage, SMPDB is now integrated into several other databases including HMDB and DrugBank. INTRODUCTION Biological pathways are the wiring diagrams of life. They provide a rich and surprisingly compact view of how genes, proteins and metabolites work together in cells, tissues or organs. In fact, most of today’s life scientists learned their biochemistry and molecular biology by studying richly annotated, carefully hand-drawn pathway diagrams found in books or on wall charts. With the advent of the internet, many biological pathway diagrams started migrating from the printed page to the web. As a result, there is now a plethora of very popular, very high-quality web-accessible pathway databases such as KEGG (1), the ‘Cyc’ databases (2,3), the Reactome database (4), WikiPathways (5) and PharmGKB (6). The advantages of using the web to illustrate and disseminate biological pathway information are manifold. These include greater accessibility, improved interactivity and enhanced functionality. However, the limitations associated with creating hyperlinked web illustrations often means that visual interactivity has to come at the expense of artistic quality or biochemical detail. This can be particularly problematic in the fields of clinical metabolomics and clinical chemistry where details about chemical structures as well as target organs, tissue locations, organelle function and physiological activity are particularly important. In an effort to make web-based biological pathway data more visually appealing and physiologically relevant, particularly for biomedical applications, we developed the Small Molecule Pathway Database or SMPDB (7). The first version of SMPDB, which was released in 2010, contained >350, colorful, artistically rendered and biochemically complete pathway illustrations describing many key aspects of human metabolism. These included hyperlinked diagrams of human metabolic pathways, metabolic disease pathways, metabolite signaling pathways and drug-action pathways. Many of these pathway diagrams included information on the tissue locations, relevant organs, organelles, subcellular compartments, protein cofactors, protein locations, metabolite locations, chemical structures and protein quaternary structures. As with many high-quality web-based pathway databases, SMPDB also provided extensive hyperlinking, browsing, searching and annotation functions along with detailed pathway descriptions and references. However, the first version of SMPDB was not without some shortcomings. In particular, it was difficult to update and maintain, it was limited in size and scope, its pathways lacked a certain degree of standardization, its physiological information on organelles and organs was incomplete and its visual interactivity (zooming and image navigation) was awkward and somewhat restricted. Furthermore, SMPDB pathway diagrams were only downloadable as static images and not available in standard formats such as BioPAX or SBML (8). While SMPDB did link to well-known databases such as DrugBank (9), HMDB (10) or UniProt (11), these databases did not link to it. In other words, SMPDB was not particularly visible to the metabolomics, drug research or systems biology communities. With the release of SMPDB 2.0, we believe we have addressed all of these shortcomings. In particular, we have developed tools to simplify SMPDB’s maintenance and enhance its illustration standards. We have also corrected and added much more physiological (tissue, organ, organelle and transporter) information, substantially improved its visual interactivity and quality, created downloadable BioPAX pathway files for all of SMPDB’s pathways and increased SMPDB’s visibility by integrating SMPDB into DrugBank, HMDB and MetaboAnalyst. Finally, we have substantially expanded the size and scope of SMPDB to include >600 pathways (a 70% increase) and have added a large number of drug metabolism and physiological action pathways. With these enhancements, we believe that SMPDB 2.0 will appeal to a much broader community of researchers and will offer users a much more enriched, interactive and informative experience. A detailed description of SMPDB 2.0 follows. INCREASED SIZE AND SCOPE When it was initially released, SMPDB (version 1.0) contained 350 hand-drawn pathways. These small molecule pathways were limited to three general categories: basic metabolism, metabolic diseases and selected drug-action pathways. Today, SMPDB 2.0 contains >600 pathways (a 70% increase) and it now includes six kinds of small molecule pathway categories including: basic metabolism, metabolic diseases, drug-action pathways, drug metabolism pathways, metabolite signaling pathways and physiological action pathways. The inclusion of drug metabolism pathways in SMPDB 2.0 was driven by user requests and the rapidly growing interest in drug metabolism in many fields of drug research and clinical metabolomics. The addition of metabolite signaling and physiological action pathways was motivated by the need to handle a larger number of drug-action pathways. It was also brought on by the growing awareness by members of the metabolomics and nutritional science communities that many metabolic pathways act at the level of organs and tissues and not only within cells. In addition to the significant numerical increase in SMPDB’s size and scope, many of the pathway diagrams in SMPDB 2.0 have been enhanced with additional cellular or physiological information. Now nearly every SMPDB pathway includes information about where the reactions occur (cellular compartment(s), organs or tissues), the site/organ of action for drugs (for drug-action pathways) or toxic metabolites (for metabolic disorders) as well as information on key membrane-bound transporters (which move drugs and metabolites in and out of almost every cell). This kind of physiological or extracellular information is rarely captured or displayed in other online pathway databases. However, because SMPDB is a human-only pathway resource, this sort of physiological, cellular, biochemical or biomedical information is particularly important. Consequently, considerable effort over the past 3 years has been put into capturing and displaying these data. As with its predecessor, SMPDB 2.0 is still strictly focused on curating human-only, small molecule-only pathways. Therefore, SMPDB only displays those pathways where small molecules (metabolites or drugs <1500 daltons) play key roles and/or where small molecules represent a significant proportion of functional entities in a given pathway. All of the pathways in SMPDB 2.0

Read the complete text